infection has not been established in pregnancy and they are not routinely recommended. In influenza virus infection complicated by pneumonia, antibacterial agents active against Staphylococcus aureus and Streptococcus pneumoniae superinfection should be used.
There are few data on infective complications of asthma or COPD in pregnancy. The latter is rare, as patients with COPD are usually male and aged over 45 years. Management is the same as for nonpregnant patients.
The incidence and mortality of pneumonia in pregnancy is similar to that in nonpregnant patients. Infants born to pregnant patients with pneumonia have been found to be born earlier and weigh less than controls. Risk factors for the development of pneumonia include anemia, asthma and use of antepartum corticosteroids and tocolytic agents. Based on the few available studies, the main pathogens causing pneumonia are S. pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae and viruses. β-Lactam and macrolide antibiotics therefore remain the antibiotics of choice in terms of both pathogen coverage and safety in pregnancy. In HIV-infected pregnant patients, recurrent bacterial pneumonia, but not Pneumocystis carinii pneumonia (PCP), is more common than in nonpregnant patients. Trimethoprim/sulfamethoxazole (cotrimoxazole) has not definitely been associated with adverse clinical outcomes despite theoretical risks. Currently it is still the treatment of choice in PCP, where mortality remains high.
In conclusion, there are few data specifically related to pregnant women with different types of LRTI. Where data are available, no significant differences compared with nonpregnant patients have been identified. In considering the use of any therapeutic agent or investigation in pregnant patients with LRTI, safety aspects must be carefully weighed against potential benefit. Otherwise, management strategies should not differ from those for nonpregnant patients. Further research in this area is warranted.
In recent years, much effort has been devoted to improving 1.2 Immune Status management strategies in community-acquired lower respiratory Delicate changes in predominantly the cellular components of tract infections (LRTIs) with emphasis on reducing the inapproprithe maternal immune system occur to enable survival of the fetus ate use of antibacterials and the chance of inducing resistance. For with its complement of 'foreign' paternal antigens. Decreases the clinician managing pregnant patients, these public health conoccur in proliferative antibody responses to soluble antigens, cellcerns run alongside the common concern that LRTI in pregnant mediated cytotoxicity, numbers of helper T lymphocytes and patients may be more frequent, exhibit atypical features and run a natural killer cell activity. [3] [4] [5] [6] [7] more severe course or may be more difficult to treat than that in Soluble factors and hormones, such as progesterone, human nonpregnant patients, in terms of using suitable antimicrobial chorionic gonadotropin, α-fetoprotein and cortisol, are also preagents. sent in maternal serum in concentrations that can mediate immunosuppression. [6] Humoral immunity on the other hand appears to be unaffected, with the observed changes in levels of 1. Changes in Pregnancy antibodies in later pregnancy probably reflecting the effects of hemodilution.
[8]
Physical Changes
Taken together, there is a theoretical risk that the physical changes to the respiratory system may adversely affect the mother's ability to clear secretions and increase her vulnerability The physical changes affecting the respiratory system during to respiratory tract infections, while the changes in maternal pregnancy are well recognized and include elevation of the diacellular immunity could potentiate the risk from infection, espephragm by up to 4cm, splaying of the thoracic cage with a 2cm cially by viral and fungal pathogens. However, robust evidence increase in transverse diameter of the chest and a 5-7cm increase substantiating these fears is lacking. in circumference of the thoracic cage as a result of relaxation of the ligamentous attachments of the ribs due to the enlarging uterus. [1] 2. Use of Antibacterials during Pregnancy Functional residual capacity is decreased by 10-25%, the largest reduction occurring in the supine position during the latter stages When considering treatment of LRTIs with antimicrobial of pregnancy. Premature airway closure and an increase in lung agents during pregnancy, the following factors should be considwater and oxygen consumption have also been noted. [2] ered: the severity of the maternal infection; the consequences of failing to treat the mother; the effect of pregnancy on drug pharma-total antibacterial prescriptions for adults in the US. [18, 19] In a cokinetics; and the potential fetotoxicity of the drugs.
British study, using a standard definition for acute lower bronchitis or lower respiratory tract illness, the incidence of lower respiratory General principles of prescribing during pregnancy are to contract illness in women aged 16-39 years was found to be 64 per sider the period of gestation, avoid new drugs, use the lowest 1000 population, almost twice the incidence in men of a similar effective dose of drug and minimize the treatment period, and use age group (36 per 1000 population). [15] The clinical burden of a single drug if possible. A gradual increase in renal function and community-acquired LRTI and its contribution to antibacterial use an increased volume of distribution during pregnancy can give rise is therefore enormous, with CAP requiring hospital admission to decreased plasma drug concentrations. [9] Conversely, protein representing only the tip of the iceberg. [20] binding falls, thereby increasing the free (active) fraction of the drug.
Etiology
As regards reports of teratogenicity, these need to be compared against a background incidence of major malformations in the There have been few robust studies examining the pathogens general population of 2-3%. [10] Drugs and chemicals are thought associated with non-pneumonic LRTI. Viruses are generally conto account for only 4-6% of these malformations. The period of sidered the main pathogens in acute bronchitis. [21, 22] Rhinoviruses, maximum susceptibility for most structural defects is the first 10 coronaviruses, influenza viruses, adenoviruses, parainfluenza viweeks after conception (i.e. up to 12 weeks pregnancy).
ruses and respiratory syncytial virus have all been implicated. [23, 24] The exact role of atypical pathogens, such as Mycoplasma pneu-
Antibacterial Use in Breast-Feeding Mothers
moniae and Chlamydia pneumoniae, and of Streptococcus pneu-Three potential problems exist for the infant when nursing moniae is unclear. In some studies, these pathogens have been mothers are treated with antibacterials. These consists of modificaimplicated in 6% or less of patients. [25] On the other hand, in a tion of bowel flora, direct effects on the infant (e.g. allergy or series of studies performed in Nottingham, UK, [15, 16, 26, 27] using sensitization) and interference with the interpretation of culture comprehensive microbiological tests in well defined cohorts of results if a workup for fever in the neonate is required. [6] Neonates patients representing the spectrum of community-acquired LRTI, (particularly premature infants) are at greatest risk from accumula-S. pneumoniae, C. pneumoniae and M. pneumoniae were identition of drugs in the breast milk because of their immature excrefied with similar frequency in non-pneumonic LRTI and pneumotory functions. nia (figure 1). Distinguishing between secondary bacterial infection, colonization and primary infection is difficult and is reflected 4. Non-Pneumonic Lower Respiratory Tract in the uncertainty concerning the role of identified bacterial patho-Infection (LRTI) gens in non-pneumonic LRTI.
There is currently no consistent and widely accepted definition 4.3 Outcome of LRTI. [11] In its broadest sense, LRTI is characterized by an acute illness with cough as its cardinal symptom, which is not Acute bronchitis is generally a self-limiting disease. Verheij et attributable to an underlying distinct illness such as asthma. This al. [13] reported that at presentation, 33% of patients were staying in loose description embraces terms such as acute bronchitis, [12, 13] bed because of symptoms, 35% had stopped daily work and 69% middle respiratory tract infection, [14] lower respiratory tract illhad problems with physical activity. Corresponding percentages 2 ness [15] and lower respiratory tract infection. [16] Community-acweeks later were 4%, 15% and 29%, respectively. Reconsultation quired pneumonia (CAP) can be readily distinguished from nonrates in the UK are high, with one in every five patients arranging pneumonic LRTI by the presence of shadowing, consistent with to see their general practitioner again for the same illness. [15] infection on a chest x-ray and is therefore discussed separately.
However, severe disease is unusual. In one analysis of LRTI in England and Wales, only 1.4% of patients required hospital ad-
Incidence
mission. [28] Visits by adults to primary-care physicians for cough in the US Clinical studies, randomized, controlled trials and subsequent are very common and have increased from 5.5 million office visits meta-analyses examining the role of antibacterials in patients with in 1980 to 10.2 million in 1994. [17] Most of these patients are acute bronchitis have found them to be of little meaningful clinical women (60%) and 75% are younger than 65 years of age. Acute benefit. [29, 30] A recent Cochrane review which included over 750 bronchitis accounts for approximately 42% of these visits, about patients aged 8 years and older from nine trials found that, at 75% of ambulatory antibacterial prescriptions and about 11% of follow-up, patients who received antibacterials for acute bronchi-This is not to say that antibacterials are never indicated in the treatment of acute bronchitis. [34] There will be a proportion of patients, about 20%, where the physician is confident that antibacterials are indicated, usually because of the presence of factors such as focal chest signs, older age of patient and coexisting disease and generally how ill the patient appears. [35, 36] Some pregnant patients may wish to avail themselves of overthe-counter cough suppressants for symptom control even though there is currently no good evidence for their effectiveness. [37] Dextromethorphan, an active ingredient in many antitussive remedies, has been hypothesized, in a study in chick embryos, to be associated with neural tube defects. However, this risk has not been substantiated by a recent case-control study involving 184 pregnant women, 128 of whom were exposed to dextromethorphan in the first trimester. [38] There were six (3.2%) major malformations in the study group compared with five (2.7%) in the control group. No cases of neural tube defects were reported in the study group. This study had 80% power to detect a 3.5-fold increase in the rate of malformations. Other theoretical concerns regarding postnatal neurodevelopment have been raised but as yet remain untested. Therefore, based on current knowledge, there is no good evidence to either support or discourage the routine use of cough suppressants for symptom control in non-pneumonic LRTI Fig. 1 . Frequency of selected pathogens across the spectrum of lower respiratory tract infection (LRTI) from studies performed in Nottingham, UK. Totals are greater than 100% because of the identification of more than one pathogen in some individuals. Tests for Chlamydiae pneumoniae were not performed in studies on patients with LRTI and in ambulatory patients with community-acquired pneumonia (ambulatory CAP). CAP (ambulatory) [26] patients showed symptoms of LRTI with focal chest signs; CAP (hospital) [27] patients showed symptoms of LRTI with radiographic confirmation of pneumonic shadowing; LRTi [15] was defined as an acute illness in a previously well patient with cough as the cardinal symptom and at least one other lower respiratory tract symptom and LRTI [16] was defined as the presence of productive cough associated with another symptom or sign of LRTI plus constitutional symptoms and prescription of antibiotics for the illness.
in pregnant patients. tis were less likely to have a cough (relative risk [RR] 0.64, 95% 5. Influenza Virus Infection CI 0.49-0.85) or abnormal lung findings (RR 0.48, 95% CI 0.26-0.89). [31] However, there were no significant differences Influenza is characterized by the abrupt onset of fever, headbetween treated and non-treated groups for presence of night ache, generalized myalgia, extreme malaise, nonproductive cough, cough, productive cough or activity limitations at follow-up or in sore throat and rhinitis. When influenza virus is circulating in a the mean duration of activity limitations. Significantly more adcommunity, approximately two-thirds of persons with relevant verse effects such as nausea, vomiting, headache, skin rash or signs and symptoms have been found to have laboratory-convaginitis were reported by patients treated with antibacterials (RR firmed influenza virus infection. [39] Of adult patients with influen-1.48, 95% CI 1.02-2.14).
za-like symptoms, fewer than half seek medical attention, and time taken off work ranges from 0.8 to 4 days. [40] Uncomplicated
Treatment of Pregnant Patients with LRTI
influenza virus infection is usually self-limiting, and in previously No studies have specifically addressed the issue of LRTI in healthy adults, alleviation of all major symptoms occurs in about 5 pregnancy. In the absence of conflicting data, management strate-days. [41] When complicated by pneumonia, fulminant respiratory gies that have been developed for non-pregnant patients should be failure may develop. Secondary bacterial infection by Staphyloapplied equally to pregnant patients.
coccus aureus and S. pneumoniae is well recognized. In line with published guidelines, we do not recommend the use Historically, influenza virus infection in pregnant patients has of antibacterials for most patients with acute bronchitis. [32, 33] In been associated with more severe disease. During the worldwide our opinion, any modest benefit accrued from their use is out-pandemic of 1918, maternal mortality was 30%, rising to 50% weighed by the disadvantages in relation to the promotion of when complicated by pneumonia. In the Asian flu epidemic of antibacterial resistance, their adverse effects and their safety in 1957-58, almost half of the women of child-bearing age who died pregnancy. Instead, we recommend the adoption of specific be-in Minnesota and New York, USA, were pregnant. In New York, havioral and multifactorial strategies aimed at educating patients this represented 10% of all influenza deaths. [42, 43] Mortality was regarding the normally self-limiting nature of acute bronchitis. [23] highest in women in the third trimester. Post-mortem studies showed that pregnant women most commonly died of fulminant Based on the above evidence, the routine use of amantadine, primary viral pneumonia, whereas nonpregnant patients died of rimantadine and the newer neuraminidase inhibitors for the treatsecondary bacterial infection. [44] Subsequent to 1958, excess mor-ment of influenza virus infection in pregnancy cannot be recomtality during interpandemic periods have not been documented. An mended. Indeed, restriction of the use of these agents to the third epidemiological study measuring hospitalizations for or death trimester may be reasonable in view of the relatively higher from acute cardiopulmonary conditions during influenza seasons influenza mortality during this period compared with the first and found that women aged 15-44 years in their third trimester of second trimesters. pregnancy were 3-4 times more likely to be hospitalized than
In influenza virus infection complicated by pneumonia, the use postpartum controls. [45] In a seroepidemiological study, Irving et of antibacterial agents with activity against the likely pathogens al. [46] used a 4-fold rise in antibody titer to determine infection that cause secondary bacterial infection is recommended. Antiviral with the influenza virus and identified intercurrent influenza virus agents may be considered although they are of unproven benefit. infection in 182 (11%) of 1659 women in the second and third Two instances of the use of amantadine to treat influenza virus trimesters of pregnancy. In that study, no significant increase in infection in pregnant women have been reported. [53, 54] However, specific medical complications was observed, but overall there the potential teratogenicity of the M2 inhibitors (amantadine and was a significantly greater number of fetal, medical and obstetric rimantadine) in contrast to the relative lack of any teratogenicity or complications than in the controls. Together these data suggest reproductive toxicity of the neuraminidase inhibitors (zanamivir that influenza virus infection is common during pregnancy, and and oseltamivir) in laboratory animals make the latter agents the while there does not appear to be the same magnitude of risk of preferred choice where indicated. [55] In all instances, the uncertain mortality as noted in earlier epidemics, hospital admission is more benefit must be weighed against the concerns regarding safety. likely, particularly in the late stages of pregnancy.
Prevention
Transplacental passage of influenza A virus has been reported but does not appear to be common. [43] In the study by Irving et In the UK, influenza virus vaccine is not recommended for al., [46] none of 138 samples of cord sera from patients infected with pregnant women who would not otherwise qualify for immunizainfluenza virus during pregnancy was positive for influenza A tion according to Departments of Health guidelines. [56] In contrast, virus-specific IgM. The authors concluded that transplacental in the US, the Advisory Committee on Immunization Practices of transfer of influenza would be a rare outcome of maternal infection the Centers for Disease Control and Prevention recently broadened in the second or third trimester. Whether influenza virus can cause their recommendations for vaccination against influenza virus congenital malformations is under debate, but seems unlikely.
infection to include women who will be in the second or third Although circulatory defects and central nervous system malfortrimester of pregnancy during the influenza season. [57] This change mations have been described, a review of the literature could not was influenced by the recent report of increased rates of hospital find convincing evidence for a definite association with pregadmissions for acute cardiopulmonary complications in pregnant nancy. [47] women, similar to that in nonpregnant women with a high-risk condition. [58] The influenza vaccine currently available in the US
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contains three strains (two type A and one type B). The vaccine is made from highly purified, egg-grown viruses that have been The efficacy and safety of the M2 ion channel inhibitors inactivated (i.e. made noninfectious) and is considered to have a (amantadine and rimantadine) and of the newer neuraminidase good safety profile during any stage of pregnancy. A study involvinhibitors (zanamivir and oseltamivir) in pregnancy have not been ing over 2000 pregnant women demonstrated no adverse fetal clearly established. There are several case studies of congenital effects associated with the vaccine. [59] However, additional data abnormalities following exposure to amantadine in pregnancy.
are still needed, and in the meantime, avoidance of the first These include cardiac anomalies (e.g. single ventricle with pultrimester where possible seems prudent. monary atresia, tetralogy of Fallot) and tibial hemimelia. [48] [49] [50] Levy et al. [51] reported one woman who gave birth to two normal 6. Community-Acquired Pneumonia infants while on treatment with amantadine. There are no published reports of the use of rimantadine, zanamivir or oseltamivir 6.1 Incidence during human pregnancy. In pregnant rats and rabbits treated with high oral doses of oseltamivir, maternal toxicity and an increase in There are few studies on treatment of pneumonia during pregminor skeletal variations were noted. [52] nancy. Most studies are retrospective in design and include few (1) Yost et al. [66] 2000 133 1.5 0/133 (0) 14/107 (13) patients (table I). In the years before 1965, the recorded incidence 6.3 Fetal Outcome of pneumonia in pregnancy was 6.3 to 8.5 per 1000 deliveries, [60, 61] Pregnant patients with pneumonia are significantly more likely which decreased in the 1970s and early 1980s to between 0.44 and to deliver before 34 weeks gestation and preterm delivery has been 0.78 per 1000 deliveries, presumably because of the introduction reported to occur in up to 43% of cases. [74] Also, infants born to of antibacterials and improvements in obstetric care. [62, 63] More mothers with pneumonia weigh significantly less than controls. recently, a small increase in the incidence of pneumonia to 1.2-2.7
One study found a difference of 150g in birth weight and a per 1000 deliveries has been noted. [64] [65] [66] As these study cohorts difference of 8% (16 vs 8%) in the frequency of low birth weight may not be directly comparable, it is unclear whether this reported (≤2500g) in cases compared with controls. [66] Perinatal mortality increase in incidence in the most recent studies is a true change appears to be unaffected. reflecting the higher proportion of pregnant women with chronic medical conditions and therefore susceptible to pneumonia, as has 6.4 Risk Factors for Development of Pneumonia been proposed. [64] Among pregnant women, maternal age and parity have not Perhaps more importantly, the incidence of pneumonia during been shown to be associated with pneumonia. [66] On the other pregnancy reported in recent studies do not differ from the estimathand, gestational age appears to be important. The risk of pneumoed incidence of CAP in young nonpregnant adults. In a Finnish nia during pregnancy is lowest in the first trimester, with 0-16% of population-based study, the age-specific incidence of communitycases occurring during this period. Mean gestational age at adacquired pneumonia per year was 6 per 1000 population for mission for pneumonia ranges from 24 to 31 weeks. [63, 66] persons aged 15-59 years. The incidence was higher in men than
The presence of anemia as a risk factor for pneumonia was first in women. [68] Other estimates from the US and UK are similar; 5-8 proposed by Benedetti et al., [62] who noted that 19 (47%) of 37 per 1000 population per year for persons aged 15-59 and 5 per pregnant patients with pneumonia had a hemoglobin level of 10 g/ 1000 for persons aged 15-79 years, respectively. [26, 69] dL or less. A further association between asthma and pneumonia during pregnancy was suggested by Richey et al., [65] who noted 6.2 Mortality that in their series, 17 (24%) of 71 patients had asthma. In a recent case-control study comprising 59 cases and 118 controls, both of Pneumonia has been cited as the third most frequent cause of these factors (haematocrit <30% and history of asthma) were indirect obstetric death in North America and is the most frequent confirmed to be independently associated with a 5-fold increased cause of fatal non-obstetric infection. [70, 71] However, in the UK, of risk for the development of pneumonia. [74] 134 indirect deaths during the period 1994 to 1996 (equivalent to a Antepartum corticosteroids given to reduce morbidity and morrate of 6.1 per 100 000 maternities), only six were due to pneumotality in the premature neonate have been found to be associated nia. Three of the six deaths due to pneumonia were in patients with with a higher rate of infectious disease (65% cases compared with concurrent cystic fibrosis. Therefore, in absolute terms, maternal 17.5% controls) with serious bacterial infections occurring in 9 death from pneumonia remains rare in the UK. This is reflected in (24%) of 37 cases (4 of these pneumonias) compared with 0 of 74 the reported maternal mortality of 0-4%, which is similar to the controls. [75] More specifically, antepartum corticosteroids have mortality from CAP in young hospitalized nonpregnant also been identified as being independently associated with pneuadults. [72, 73] monia during pregnancy. [74] Tocolytics, administered to halt labor, have been associated of mild pneumonia and improves satisfactorily with empiric antibacterials. with the development of pneumonia and, through the promotion of pulmonary edema, also increase the risk of subsequent respiratory 6.6 Pathogens insufficiency. [74, 76] They are therefore not recommended for use in pregnant patients with pneumonia. [77] There are no detailed studies of the microbial agents involved No other risk factors have been definitely identified from in pneumonia during pregnancy. The available data are derived studies of pregnant patients with pneumonia. However, large mainly from observational, and often retrospective, studies where studies in nonpregnant adults have found smoking to be strongly only routine microbiological investigations have been used. Spuassociated with the development of pneumonia and also invasive tum and blood cultures were the main methods of diagnosis. Based pneumococcal disease. [78, 79] Such an association would be expecon four recent studies, the range of pathogens identified is similar ted to hold true for pregnant women as well and represents an to that described for hospitalized nonpregnant adults with CAP important risk factor that is potentially modifiable. This is espe- (table II) . cially relevant, since up to a third of pregnant women smoke. [80] S. pneumoniae was the most common organism identified, followed by H. influenzae. There were few cases of infection by 6.5 Diagnosis atypical pathogens, such as M. pneumoniae, or viruses. This may be partly explained by the inconsistent use of serological tests. Infection with Legionella spp. has been documented but is rare.
The diagnosis of pneumonia in a pregnant patient is not always
There is no good evidence to suggest an increased risk of Legioneasy. In Madinger and colleagues' [63] series of 25 patients, 5 (20%) naire's disease during pregnancy or any increase in severity of were initially misdiagnosed, 1 was initially treated for suspected illness. pyelonephritis, 2 had surgery for suspected appendicitis and 2
Coxiella burnetii (Q fever) is occasionally implicated in pneuwere thought to have preterm labor with no predisposing cause monia during pregnancy. In the largest reported series of 1383 identified. Similarly, Yost et al. [66] found that 14 (10.5%) of 133 infections identified over a 13-year period, 15 patients had Q fever patients were initially misdiagnosed. during pregnancy. [84] These patients reported significantly more One of the main challenges in diagnosing pneumonia during pregnancy is differentiating between respiratory symptoms related to physiological changes and those related to disease. Dyspnea, in particular, is common during pregnancy. It is experienced by 50% of women at 19 weeks gestation and up to 76% at 31 weeks. [81] Physiologic dyspnea characteristically begins early in pregnancy and improves or plateaus as term approaches. It does not usually interfere with daily activities and rarely occurs at rest. Clinical experience and a high index of suspicion are therefore crucial in identifying patients with disproportionate dyspnea in whom pneumonia must be considered. Associated cough should arouse clinical suspicion of an underlying cause. Clinical examination may reveal abnormal chest signs. However, a firm diagnosis of pneumonia can be made only with the aid of a chest radiograph. Therefore, given the appropriate clinical scenario, the risk of misdiagnosing pneumonia is greater than the small risk from radiation exposure. [82] The differential diagnosis of alveolar shadowing on a chest x-ray in the context of pregnancy includes noncardiogenic pulmonary edema in preeclampsia and eclampsia, pulmonary edema secondary to tocolytic agents, aspiration pneumonitis and, rarely, choriocarcinoma with pulmonary metastases. [83] Such conditions are rare in the first trimester and an argument could be made for not performing chest x-rays at this stage in a pregnant woman who presents with the clinical features Table II . Pathogens implicated in community-acquired pneumonia during pregnancy (n = 161) [62] [63] [64] [65] No. patients (%)
Bacterial pathogens

Streptococcus pneumoniae
28 (17) Haemophilus influenzae 9 (6) contact with farm or newborn animals than other patients with tions are detailed in the guidelines on management of CAP issued acute Q fever. Fetal outcome was poor. The fetus was aborted in by national bodies. [33, [87] [88] [89] It is outside the scope of this paper to ten patients and born prematurely in three. Most human infection discuss the relative merits of the different severity assessment with C. burnetii is due to inhalation of the organism from aerosols tools recommended. Common to all is the fact that these tools were generated by pregnant farm animals. [85] C. burnetii has been isolatdeveloped mainly in hospitalized nonpregnant adults and there are ed from the placentas of asymptomatic women, and human-tono data specifically relating to pregnant patients. Yost et al. [66] human transmission during delivery of the fetus and placenta has retrospectively applied the 1993 American Thoracic Society been reported. [86] Hence, although Q fever during pregnancy is (ATS) guidelines to 119 pregnant women with pneumonia admitrare, it is important to make the diagnosis in view of the impact on ted to hospital. Twenty-two (96%) of the 23 women who had a fetal outcome and the wider public health issues. In addition, complicated course were correctly identified, based on the prespregnant women are advised to avoid being involved with lambing ence of any of the following: coexisting illness (including asthma, or calving.
diabetes, COPD, heart failure, chronic renal failure, chronic liver Anaerobic organisms are not usually implicated in CAP unless disease or a postsplenectomy state); altered mental status; respirathere is evidence of aspiration. In the pregnant patient, anaerobic tory rate >30/min; temperature >38.3°C; white cell count <4000 or infection may need to be considered in pneumonia occurring >30 000 cells/mm 3 ; arterial oxygen tension (PaO2) <60mm Hg or during the peripartum period.
arterial carbon dioxide tension >50mm Hg; creatinine >1.2 mg/dL or chest radiographic evidence of multilobar involvement or pleu-6.7 Treatment ral effusion. The ATS guidelines have since been updated and we recommend that where possible, national guidelines are consulted. We favor the use of the severity assessment tool detailed in the
Severity Assessment
2001 British Thoracic Society CAP management guidelines in The most important decision in the management of CAP is view of its simplicity and hence ready applicability (figure 2). where to treat the patient. This is perhaps even more important for Ultimately, clinical judgement exercised at the individual level pregnant patients. Numerous severity assessment tools to help guide this decision have been evaluated and specific recommenda-remains essential. Fig. 2 . Severity assessment in the management of CAP (reproduced from the British Thoracic Society, [89] Thorax 2001; 56 Suppl. 4: IV1-64, with permission from the BMJ Publishing Group). CAP = community-acquired pneumonia; CXR = chest x-ray; FiO2 = inspired oxygen fraction; PaO2 = oxygen partial pressure.
Appropriate Antimicrobial Agents
was suggested, but there was only a small number of cases, mostly In the absence of severe maternal toxicity there is no evidence inguinal hernia; therefore no causal relationship could be estabto suggest that penicillins are associated with an increased risk of lished. malformations or other forms of fetal toxicity in human preg-Although no specific data are available, it is assumed that nancy. If the mother is allergic to penicillin, any fetal toxicity is doxycycline, like other tetracyclines, can also cause fetal staining likely to be secondary to maternal toxicity. [90] In a paired analysis of the teeth and depression of bone growth. A report from a of cases with congenital abnormalities and matched controls, Hungarian surveillance project identified 56 malformed infants treatment of pregnant patients with seven studied cephalosporins whose mothers had used doxycycline in pregnancy. However, did not seem to present a detectable teratogenic risk to the fetus. [91] there was no convincing pattern of abnormalities and no relation-Erythromycin is not associated with an increased risk of malship between drug use and the critical period of development of formations or other forms of fetal toxicity in human pregnancy. [90] any of the malformations. The authors believed that the significant In a prospective, controlled, multicenter study, 122 of 157 association between doxycycline use and total malformations women were exposed to clarithromycin during the first trimescould be attributed to recall bias and that the risk of doxycycline ter. [92] There were no significant differences between exposed and was very low. [52, 96] unexposed groups in the rates of major and minor malformations.
In summary, tetracyclines should generally be avoided in preg-The higher rate of reported spontaneous abortions in the exposed nancy group warrants further study. In a retrospective surveillance study
There are limited data available on the use of quinolones during of 143 mothers and their 149 infants, five infants were identified human pregnancy. Quinolones have a high affinity for bone tissue, with major malformations, three with minor malformations, and with arthralgia and tendonitis reported in adolescents and adults. four with undescended testicles likely to resolve with time. [93] The Furthermore, young animals given ciprofloxacin developed observed rate of 3.4% (95% CI 0.5-6.3) for major malformations arthropathy with cartilage erosion. No reports of this type of was not statistically significantly different from an expected rate problem have been reported following in utero exposure in human of 2.8% based on earlier national data. There was no consistency pregnancy. The clinical significance of these findings for the fetus across types of major malformations.
is not known. A review of 350 pregnancies with exposure to No congenital anomalies were observed among the infants of ciprofloxacin found no increased risk of either spontaneous aborten mothers who were treated with azithromycin during the first tion or congenital malformations. No specific syndrome of defects trimester of pregnancy in one series [52] . No adverse effects were has been reported. [90] observed in the infants of two women who were treated with Nevertheless, the use of quinolones in persons under 18 years azithromycin during the second trimester of pregnancy. [52] old and in pregnant women is not routinely recommended. The newer macrolides, clarithromycin and azithromycin, are
Only a small number of reports involving human pregnancies reported to have fewer gastrointestinal adverse effects than eryhave suggested that metronidazole may cause fetal toxicity. [97] thromycin. [94] This is an important consideration in pregnant pa-Although the incidence of total malformations was apparently tients.
increased in neonates exposed to metronidazole during the first Exposure to tetracyclines prior to 12 weeks has not been trimester, no pattern of defects was evident. One case report associated with an increased risk of fetal toxicity. However, addescribed two children exposed to metronidazole during the fifth ministration of tetracyclines in the second or third trimesters of to seventh gestational weeks who were born with midline facial pregnancy can cause yellow-brown staining and banding of the defects. [97] The concordance between the defects noted in these teeth of the child and reversible growth retardation of the long two cases has been proposed as a significant indicator of a teratobones. [95] There may be up to a 40% depression of bone growth, genic effect that had been previously overlooked. In contrast to especially of the fibula in preterm pregnancies. Although there are these observations, the accumulated data on more than 1300 births a number of case reports of congenital anomalies in human preginvolving prenatal exposure to metronidazole suggest no increase nancies following tetracycline use by the mother, the Collaborain congenital anomalies. [98] [99] [100] [101] In addition, a retrospective cohort tive Perinatal Project was not able to establish a causal relationship study involving nearly 1400 exposed pregnancies did not detect an with tetracyclines among the children of 341 women treated with increase in congenital abnormality or low-birth-weight infants. [98] tetracycline during the first 4 lunar months of pregnancy. [90] Similarly, the frequency of congenital anomalies was not increased No congenital anomalies in infants born to women who took among the children of 1336 women treated with tetracycline at any vancomycin during pregnancy have been reported, in epidemiotime during pregnancy. A possible association with minor defects logical studies. No evidence of auditory or renal damage was found among ten infants whose mothers had been treated with 7. HIV Infection and Pneumonia vancomycin during the second or third trimester of pregnancy. [102] No increase in abnormal outcomes was noted among the infants The prevalence of human immunodeficiency virus (HIV) infecof 104 women treated with clindamycin in the second or third tion in mothers living in London has risen from 0.032% in 1988 to trimester of pregnancy, as part of a controlled trial of therapy to 0.19% in 1996. [106] The majority (58%) are mothers infected prevent low birth weight. [103] In a surveillance study of Michigan through heterosexual contact. This trend is also evident in the US, Medicaid recipients involving 229 101 pregnancies conducted bewhere over 80% of women with AIDS are of reproductive age. [107] tween 1985 and 1992, 647 neonates had been exposed to clinda-Bacterial infections are the most common respiratory complicamycin in the first trimester. [104] A total of 31 (4.8%) major birth tions in patients with HIV infection. [108] The reported incidence of defects were observed of which 28 were expected. bacterial pneumonia ranges from 5.5 to 12.5 per 100 personyears. [109] [110] [111] A Swiss cohort found that recurrent bacterial pneumonia was the only AIDS-defining event which was significantly
Suggested Treatments According to Disease Severity
more common in HIV-infected pregnant women compared with Antibacterial therapy is usually empirical and the choice of nonpregnant women (RR 8.0, 95% CI 1.7-37). [112] Otherwise, no antibiotics in the pregnant patient with CAP is influenced by robust evidence exists to indicate that community-acquired LRTI disease severity and therefore site of treatment, likely pathogens should behave any differently in HIV-infected pregnant women. involved based on local epidemiology, and drug safety. Suggested
Although Pneumocystis carinii pneumonia (PCP) has not been antibiotics for use in different patient groups stratified according shown to be more common in HIV-infected pregnant women than to site of care and disease severity are given in table III. These are nonpregnant women, it is still the most common cause of AIDSdrawn from recently published guidelines by national bodies in the related death in pregnant women in the US. [113] A recent review of UK and US with some modification.
the literature identified 22 reported cases of PCP in pregnant Apart from antibiotics, the appropriate administration of supwomen. [114] All had previously undiagnosed HIV infection. Clinplemental oxygen and intravenous fluids, where indicated, must ical presentation of disease was not altered as reported previousnot be ignored.
ly. [115] However, maternal and fetal outcomes were dismal. Thirteen (59%) patients developed respiratory failure requiring 6.7.4 Vaccination mechanical ventilation and 11 (50%) patients died. There were five stillbirths and four other babies died shortly after delivery. The pneumococcal vaccine is recommended for use in patients Patients presenting in the third trimester appeared to have a better at high risk of developing severe pneumococcal infection. [105] prognosis. These figures compare poorly with those for non-These recommendations apply to some women of child-bearing pregnant patients with HIV disease and PCP. Unfortunately, there age (e.g. patients with asplenia or sickle-cell anemia). As the is a lack of studies directly comparing HIV-infected pregnant safety profile of the pneumococcal vaccine in pregnancy is untestwomen with nonpregnant women, and the more severe disease ed, women at high risk of pneumococcal disease should ideally be depicted in these case reports may reflect publication bias. vaccinated before pregnancy. 
Hospital treated (non-severe)
The use of antipneumococcal fluoroquinolones as an alternative agent is Amoxicillin 500mg-1.0g 8-hourly PO and new generation macrolide not recommended in view of limited data regarding their safety during (e.g. clarithromycin 500mg 12-hourly PO) pregnancy.
Hospital treated (severe)
Alternatives to cefuroxime include cefotaxime and ceftriaxone Cefuroxime 1.5g 8-hourly IV and new generation macrolide (e.g. clarithromycin 500mg 12-hourly IV) IV = intravenous; PO = oral. due to its folate antagonist activity. Nevertheless, trimethoprim/ sulfamethoxazole is the treatment of choice for all patients with PCP, regardless of disease severity and the risks from adverse drug effects. As with nonpregnant patients, adjunctive corticosteroids are indicated for patients with PCP pneumonia presenting with hypoxemia (PaO 2 <8.3 kPa). There is little experience with the use in pregnant patients of alternative agents active against P. carinii.
Chemoprophylaxis for PCP in HIV-infected pregnant women is recommended using trimethoprim/sulfamethoxazole. If there are concerns regarding the theoretical risks of teratogenicity, aerosolized pentamidine, which has minimal systemic absorption, may be used as an alternative agent during the first trimester.
Summary
Few studies have been performed examining the issue of community-acquired LRTI during pregnancy. Pneumonia is the best studied. Currently, there are few data to indicate that communityacquired LRTI present differently or are more severe during pregnancy. However, pregnancy poses special concerns regarding the risks from adverse drug effects. In general, management strategies developed for nonpregnant patients apply equally well to pregnant patients. Antibiotic options are more limited and in all instances, the benefits of antibiotic use must be weighed carefully against their risks and adverse effects. A summary of the safety of selected antimicrobials in pregnancy is provided in table IV. Key to authors' classification: ✓ = adverse effects may have been shown in preclinical animal studies but published human studies do not show any adverse effects; ▲ = animal studies have revealed adverse effects in the fetus and there are no controlled studies to determine risk; × = positive evidence of fetal risk but the benefits from use in pregnancy may be acceptable despite the risk; B = animal studies do not indicate a risk to the fetus and there are no controlled human studies, or animal studies do show an adverse effect on the fetus but well controlled studies in pregnant women have failed to demonstrate a risk to the fetus; C = studies have shown that the drug exerts animal teratogenic or embryocidal effects, but there are no controlled studies in women, or no studies are available in either animals or women; D = positive evidence of human fetal risk exists, but benefits in certain situations (e.g. life-threatening situations or serious diseases for which safer drugs cannot be used or are ineffective) may make use of the drug acceptable despite its risks. nancy. [116] However, no characteristic pattern was observed among 
